Immunotherapy has become an increasingly pivotal approach in the management of uterine (endometrial) and cervical malignancies. Immune checkpoint inhibitors, particularly pembrolizumab and dostarlimab, have demonstrated remarkable improvements in overall survival, predominantly among patients exhibiting deficient mismatch repair (dMMR), microsatellite instability-high (MSI-H) status, or elevated PD-L1 expression. In cervical carcinoma, integrating checkpoint inhibitors with concurrent chemoradiotherapy has yielded enhanced therapeutic outcomes in high-risk populations, while antibody–drug conjugates such as tisotumab vedotin have broadened the therapeutic landscape. Although challenges including therapeutic resistance and immune-related adverse events remain, recent international clinical trials substantiate that immunotherapy is redefining current standards of care and paving the way for the advancement of precision oncology.

Immunotherapy, uterine cancer, cervical cancer

Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Sessa, (2021). Annals of Oncology, 32(12), 1636–1652. https://doi.org/10.1016/j.annonc.2021.09.005

Makker, V., Colombo, N., Casado Herraez, A., Santin, A. D., Colomba, E., Miller, D. S. New England Journal of Medicine, 386(5), 437–448. https://doi.org/10.1056/NEJMoa2108330

Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., (2022). Clinical activity and safety of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced mismatch repair-deficient endometrial cancer. Journal of Clinical Oncology, 40(15), 1626–1636. https://doi.org/10.1200/JCO.21.01355

Tewari, K. S., Monk, B. J., Vergote, I., Miller, A., de Melo, A. C., Kim, H. S., … & Oaknin, A. (2022). Survival with cemiplimab in recurrent cervical cancer. New England Journal of Medicine, 386(6), 544–555. https://doi.org/10.1056/NEJMoa2112187

Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., … & O'Malley, D. M. (2023). Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. Journal of Clinical Oncology, 41(19), 3495–3505. https://doi.org/10.1200/JCO.23.00340

Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L. M., Cibula, D., … & Vergote, I. (2021). The Lancet Oncology, 22(5), 609–619. https://doi.org/10.1016/S1470-2045(21)00056-5

Eskander, R. N., Tewari, K. S., Randall, L. M., Monk, (2023). Gynecologic Oncology, 172(2), 338–346. https://doi.org/10.1016/j.ygyno.2023.07.017

Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., (2020) Journal of Clinical Oncology, 38(1), 1–10. https://doi.org/10.1200/JCO.19.02105

Liu, Y., Chen, Z., & Zhаo, H. (2022). PD-1 disruption enhаncesCАR T-cell persistence in hemаtologic mаlignаncies. NаtureMedicine, 28(5), 1024–1032)https://pubmed.ncbi.nlm.nih.gov/30327605/

Wаng, H., Kаur, G., Sаnkin, А. I., Chen, F., Guаn, F., & Zаng, X. (2019). Immune checkpoint blockаde аnd CАR-T cell therаpyin hemаtologic mаlignаncies.Journаl of Hemаtology & Oncology, 12(1), 59. https://pubmed.ncbi.nlm.nih.gov/31186046/

Yoon, D. H., Osborn, M. J., Tolаr, J., & Kim, C. J. (2018). Incorporаtion of immune checkpoint blockаde into CАR-T cells: Combinаtion or built-in CАR-T.Internаtionаl Journаl of MoleculаrSciences, 19(2), 340 https://pmc.ncbi.nlm.nih.gov/аrticles/PMC5855562/